Literature DB >> 17593040

The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.

Fernando Tjin Asjoe1, Sevilay Altintas, Manon T Huizing, Cecile Colpaert, Erik Van Marck, Jan B Vermorken, Wiebren A Tjalma.   

Abstract

The Van Nuys Prognostic Index 1996 (VNPI), based upon tumor size, pathological grade and tumor margins, is a guideline for the treatment of ductal carcinoma in situ (DCIS). It was thought to strongly decrease overtreatment. In 2003, age was added to the index as a fourth prognostic factor. We examined changes in treatment modality after applying the VNPI retrospectively and investigated if the addition of age to the Index causes a shift in treatment. The influence of each prognostic factor on disease-free survival (DFS) was calculated. We performed a retrospective file study of DCIS patients treated between 1985 and 2003 at the University Hospital, Antwerp. Patients were assigned a Van Nuys Score 1996 and 2003. The influence of tumor size, pathological grade, tumor margins and age on DFS was calculated with the Kaplan-Meier method and the log-rank test. We identified 104 DCIS cases with a median follow-up of 36 months. Twelve patients showed recurrence (11.5%), of whom seven were invasive (58%). Seventeen of the 29 women diagnosed before 1997 were undertreated according to the VNPI 1996 and six of them showed recurrence. The remaining three recurrences were correctly treated. Seventy-five patients diagnosed after 1997 were all treated according to the VNPI 1996 and only three had a recurrence. The introduction of age caused no significant shift in treatment modalities. Significant differences in DFS were seen between large (>41 mm) and small (<15 mm) tumors (p = 0.0074), old (>60 years) and young (<40 years) patients (p = 0.024) and Van Nuys Subgroup 2 and 3 (p = 0.04). Tumor margins and pathological grade showed no significant difference in DFS. The VNPI can be a useful tool in the treatment of DCIS. However, this Index is not evidence-based, using a relatively small retrospective series of patients. The validity of the modified VNPI must be prospectively confirmed with large numbers of DCIS patients.

Entities:  

Mesh:

Year:  2007        PMID: 17593040     DOI: 10.1111/j.1524-4741.2007.00443.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

Review 1.  Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Authors:  Tatyana Shamliyan; Shi-Yi Wang; Beth A Virnig; Todd M Tuttle; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

2.  Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?

Authors:  Taeryung Kim; Heung Kyu Park; Kyung Hee Lee; Kwan Il Kim; Kyu Chan Lee; Jeong Suk Ahn; Kwang-Pil Ko
Journal:  Springerplus       Date:  2014-08-05

Review 3.  Current view on ductal carcinoma in situ and importance of the margin thresholds: A review.

Authors:  A Van Cleef; S Altintas; M Huizing; K Papadimitriou; P Van Dam; W Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2014

4.  Is anti-hormonal treatment in DCIS of the breast a need?

Authors:  Waa Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2016-09

5.  A Comparison of Predicted Ipsilateral Tumor Recurrence Risks in Patients With Ductal Carcinoma in Situ of the Breast After Breast-Conserving Surgery by Breast Radiation Oncologists, the Van Nuys Prognostic Index, the Memorial Sloan Kettering Cancer Center DCIS Nomogram, and the 12-Gene DCIS Score Assay.

Authors:  Rachel Y Lei; Dennis L Carter; Andrew G Antell; Molly A Nowels; Shannon P Tole; John P Bennett; Michelle Turner; Frederick L Baehner; Charles E Leonard
Journal:  Adv Radiat Oncol       Date:  2020-11-01

6.  Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project.

Authors:  J Thomas; A Evans; J Macartney; S E Pinder; A Hanby; I Ellis; O Kearins; T Roberts; K Clements; G Lawrence; H Bishop
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

7.  The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.

Authors:  Islam M Miligy; Michael S Toss; Sho Shiino; Georgette Oni; Binafsha M Syed; Hazem Khout; Qing Ting Tan; Andrew R Green; R Douglas Macmillan; John F R Robertson; Emad A Rakha
Journal:  Br J Cancer       Date:  2020-08-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.